All In Biotech

Drug Trial Radar · NCT00830674

A Study of KRN23 in X-linked Hypophosphatemia

A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia

Last checked: Nov 20, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Dec 2008

Primary completion

Dec 2011

Study completion May 2013

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Kyowa Hakko Kirin Pharma, Inc.
First posted
Jan 28, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of KRN23 after a single intravenous (IV) and subcutaneous (SC) administration in XLH patients.

Conditions

  • X-linked Hypophosphatemia

Interventions

  • PlaceboDrug

    single dose IV or SC administration

  • KRN23Drug

    Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: Up to 7 weeks after dosing (maximally 11 weeks)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Yale University School of Medicine

    New Haven, Connecticut

  • General Clinical Research Center, Indiana University School of Medicine

    Indianapolis, Indiana

  • Duke Clinical Research Unit

    Durham, North Carolina

  • University of Texas Health Science Center at Houston

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.